3.63
0.12 (3.42%)
Previous Close | 3.51 |
Open | 3.53 |
Volume | 67,524 |
Avg. Volume (3M) | 81,166 |
Market Cap | 1,289,038,464 |
Price / Earnings (Forward) | 59.88 |
Price / Sales | 1.32 |
Price / Book | 1.06 |
52 Weeks Range | |
Earnings Date | 17 Apr 2025 |
Profit Margin | -22.05% |
Operating Margin (TTM) | -17.68% |
Diluted EPS (TTM) | -0.550 |
Quarterly Revenue Growth (YOY) | -5.80% |
Total Debt/Equity (MRQ) | 48.54% |
Current Ratio (MRQ) | 2.09 |
Operating Cash Flow (TTM) | -36.05 M |
Levered Free Cash Flow (TTM) | -188.42 M |
Return on Assets (TTM) | -1.77% |
Return on Equity (TTM) | -16.25% |
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
Stock | Evotec SE | Mixed | Bearish |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -4.0 |
Average | -2.00 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
% Held by Institutions | 2.52% |
Ownership
Name | Date | Shares Held |
---|---|---|
Lighthouse Investment Partners, Llc | 31 Dec 2024 | 39,803 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
24 Apr 2025 | Announcement | Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb |
17 Apr 2025 | Announcement | Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results |
10 Apr 2025 | Announcement | Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 |
04 Mar 2025 | Announcement | Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb |
26 Feb 2025 | Announcement | Evotec Announces Change in Management Board |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |